Clinical reference Biomarker Directory
Back to directory

VEGFC

Emerging

VEGF-C drives lymphangiogenesis and is studied as a research marker for lymph node metastasis risk in cancer.

Also known as VEGF-C vascular endothelial growth factor C
In plain language

VEGF-C helps tumors build new lymphatic vessels, which can give cancer cells extra pathways to spread to lymph nodes. It's an active area of cancer research, though not yet a standard clinical test.

Biomarker & context

Vascular endothelial growth factor C (VEGF-C) drives lymphangiogenesis (new lymphatic vessel formation), distinct from VEGF-A's role in blood vessel formation targeted by more familiar anti-angiogenic cancer drugs.

What it indicates

Elevated tumor VEGF-C is associated with lymph node metastasis risk across several cancer types, since new lymphatic vessels can provide additional routes for tumor cells to spread to lymph nodes.

Diagnosis & clinical testing

Measured via tissue immunohistochemistry or research-grade serum assay; VEGF-C is not yet a standardized clinical diagnostic test, functioning primarily as a research biomarker for metastatic risk assessment.

Guiding treatment

VEGF-C is being studied as a biomarker for response to anti-angiogenic and anti-lymphangiogenic therapies, an active area of oncology drug development, though no VEGF-C-specific therapy is yet in routine clinical use.

Clinical significance

An active area of anti-lymphangiogenic drug development research, not yet a standardized clinical test.

References
  1. General oncology reference literature on VEGF-C in lymphangiogenesis and lymph node metastasis research.